Xtandi (enzalutamide) Disease area(s): Oncology Manufacturer(s): Astellas/Pfizer 2024 Sales (USD): $7.94 billion Why it sold so well: In 2024, Astellas Pharmas Xtandi, co-marketed with Pfizer, posted strong sales growth, with revenues reaching 703.1 billion ($4.64 billion) for the first nine months (April 1, 2024 to December 31, 2024), marking a 25.6% increase compared to the same period in the previous year
De plus, le glutathion est rput pour ses effets claircissants sur la peau, ce qui en fait un ingrdient populaire dans de nombreux produits de soins de la peau
If it's that bad, get the surgery
Science 165 , 11391140 (1969)
Serious AEs were less frequent with semaglutide, though discontinuation rates increased as baseline BMI decreased
Tracking your progress: beyond the scale If you are evaluating whether semaglutide is "working" based solely on the bathroom scale, you are missing most of the picture